SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma-Reference-Cited by-同舟云学术

SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma

Published:2024-01-10 Issue:4 Volume:16 Page:243-256
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Wang Xuan¹,Pan Hongming²,Cui Jiuwei³,Chen Xiao³,Yoon Won-Hee⁴,Carlino Matteo S⁴⁵,Li Xin⁶,Li Hui⁷,Zhang Juan⁶,Sun Jingchao⁶,Guo Jun¹,Cui Chuanliang¹^ORCID

Affiliation:

1. Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

2. Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

3. The First Hospital of Jilin University, Changchun, China

4. Blacktown Cancer and Haematology Centre, Blacktown, NSW, Australia

5. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

6. BeiGene (Beijing) Co., Ltd., Beijing, China

7. BeiGene (Shanghai) Co., Ltd., Shanghai, China

Funder

BeiGene, Ltd.

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/imt-2023-0130

Reference41 articles.

1. Progress in radiotherapy and expression of PD-L1 in esophageal cancer

2. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

3. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

4. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

5. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study;Journal of Cancer Research and Therapeutics;2024-08